Clinical Trial Update: Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) [Phase 4]

View source ↗

Summary

Phase 4 trial comparing rivaroxaban once daily to dose-adjusted vitamin K antagonist for biomarkers in patients with acute decompensated heart failure and atria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Rivaroxaban (rivaroxaban)
• Vitamin K antagonists (dose-adjusted)

Snippet

Sponsor: Yonsei University | Conditions: Acute Heart Failure | Phase 4 | Status: UNKNOWN